126 related articles for article (PubMed ID: 35510369)
21. Specific T-cell responses for guiding treatment with convalescent plasma in severe COVID-19 and humoral immunodeficiency: a case report.
Nyström K; Hjorth M; Fust R; Nilsdotter-Augustinsson Å; Larsson M; Niward K; Nyström S
BMC Infect Dis; 2022 Apr; 22(1):362. PubMed ID: 35410137
[TBL] [Abstract][Full Text] [Related]
22. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
23. Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea.
Nham E; Ko JH; Song KH; Choi JY; Kim ES; Kim HJ; Kim B; Lim HY; Kim KC; Jang HC; Lee KH; Song YG; Baek YJ; Ahn JY; Choi JY; Kim YC; Park YS; Choi WS; Bae S; Kim SH; Kang ES; Jeong HW; Kim SW; Kwon KT; Kim SS; Peck KR
Front Immunol; 2022; 13():968105. PubMed ID: 36211416
[TBL] [Abstract][Full Text] [Related]
24. Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19.
Zahra FT; Bellusci L; Grubbs G; Golding H; Khurana S
Ann Rheum Dis; 2022 Jul; 81(7):1044-1045. PubMed ID: 35144925
[No Abstract] [Full Text] [Related]
25. The burden of SARS-CoV-2 in patients receiving chimeric antigen receptor T cell immunotherapy: everything to lose.
Luque-Paz D; Sesques P; Wallet F; Bachy E; Ader F
Expert Rev Anti Infect Ther; 2022 Sep; 20(9):1155-1162. PubMed ID: 35838042
[TBL] [Abstract][Full Text] [Related]
26. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19.
Majumder J; Minko T
AAPS J; 2021 Jan; 23(1):14. PubMed ID: 33400058
[TBL] [Abstract][Full Text] [Related]
27. Isotyping and quantitation of the humoral immune response to SARS-CoV-2.
Goyins KA; Yu JJ; Papp SB; Beddard R; Murthy AK; Chambers JP; Arulanandam BP
Exp Biol Med (Maywood); 2022 Jun; 247(12):1055-1060. PubMed ID: 35369776
[TBL] [Abstract][Full Text] [Related]
28. SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection.
Schuh AJ; Satheshkumar PS; Dietz S; Bull-Otterson L; Charles M; Edens C; Jones JM; Bajema KL; Clarke KEN; McDonald LC; Patel S; Cuffe K; Thornburg NJ; Schiffer J; Chun K; Bastidas M; Fernando M; Petropoulos CJ; Wrin T; Cai S; Adcock D; Sesok-Pizzini D; Letovsky S; Fry AM; Hall AJ; Gundlapalli AV
Microbiol Spectr; 2022 Aug; 10(4):e0124722. PubMed ID: 35856710
[TBL] [Abstract][Full Text] [Related]
29. The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors.
Kroemer M; Boullerot L; Ramseyer M; Spehner L; Barisien C; Gravelin E; Renaudin A; Cognasse F; Gallian P; Hermine O; Lacombe K; Tiberghien P; Adotévi O
Front Public Health; 2022; 10():816848. PubMed ID: 35372242
[TBL] [Abstract][Full Text] [Related]
30. Passive immunization and its rebirth in the era of the COVID-19 pandemic.
Pavia CS; Wormser GP
Int J Antimicrob Agents; 2021 Mar; 57(3):106275. PubMed ID: 33400975
[TBL] [Abstract][Full Text] [Related]
31. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
[TBL] [Abstract][Full Text] [Related]
32. New generation of vaccines and convalescent plasma therapy for management of CoV-2: Perspectives from the UK and potential deployment in the current global pandemic.
Seghatchian J
Transfus Apher Sci; 2021 Feb; 60(1):103051. PubMed ID: 33461918
[No Abstract] [Full Text] [Related]
33. SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients?
Ameratunga R; Leung E; Woon ST; Chan L; Steele R; Lehnert K; Longhurst H
J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2267-2273. PubMed ID: 35752434
[TBL] [Abstract][Full Text] [Related]
34. Neutralizing antibody levels against SARS-CoV-2 variants of concern Delta and Omicron in vaccine breakthrough-infected blood donors.
Franchini M; Focosi D; Mengoli C; Percivalle E; Sammartino JC; Ferrari A; Zani M; Glingani C; Baldanti F
Transfusion; 2022 Jun; 62(6):1171-1176. PubMed ID: 35426131
[TBL] [Abstract][Full Text] [Related]
35. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
36. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines.
Fernandes Q; Inchakalody VP; Merhi M; Mestiri S; Taib N; Moustafa Abo El-Ella D; Bedhiafi T; Raza A; Al-Zaidan L; Mohsen MO; Yousuf Al-Nesf MA; Hssain AA; Yassine HM; Bachmann MF; Uddin S; Dermime S
Ann Med; 2022 Dec; 54(1):524-540. PubMed ID: 35132910
[TBL] [Abstract][Full Text] [Related]
37. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
38. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
Takamatsu Y; Imai M; Maeda K; Nakajima N; Higashi-Kuwata N; Iwatsuki-Horimoto K; Ito M; Kiso M; Maemura T; Takeda Y; Omata K; Suzuki T; Kawaoka Y; Mitsuya H
J Virol; 2022 Feb; 96(4):e0155121. PubMed ID: 34818068
[TBL] [Abstract][Full Text] [Related]
39. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
40. New challenges to fighting COVID-19: Virus variants, potential vaccines, and development of antivirals.
Chen J; Lu H
Biosci Trends; 2021 May; 15(2):126-128. PubMed ID: 33746183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
